anti-CD19 immunotoxin HD37 (scFv)-DT

This immunotoxin was achieved by conjugating/fusing the Anti-CD19 scFv to Diphtheriatoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to cancer cells. Once bind, the toxin enters cells by receptor-mediated endocytosis, then Before the N-terminal 193 amino acids corresponding to the catalytic domain of DT enzyme; -II binding and elongation factor into the eukaryotic cell; the cell can catalyze specific elongation factor EF2 amide His699 of diphtheria ADP2 ribosylation occurs; thereby preventing protein synthesis and causes cell death. It was designed for treatment of Head and neck squamous cell cancer or bladder cancer.